Cerene Cryotherapy launches free perimenopause education series

Cerene Cryotherapy launched its free Know Your Flow series with a perimenopause-focused event called Let’s Pause, putting menstrual and midlife education at the center of a branded community push. The company said the series is meant to make those topics more understandable, accessible and empowering for women, an aim that lands in a market where many people still reach perimenopause with little baseline information.

The series is not being sold as a clinic visit or a product demo. Cerene said it will include two event formats, including Let’s Pause, and that the events are free. That makes the access question sharper: lower-cost education can reach women who are not yet seeking care, but it also serves as a way for a device company to build familiarity and trust before symptoms become severe enough to prompt treatment decisions.

That commercial context matters because Cerene’s parent company, Channel Medsystems, has spent years building in women’s midlife health. The U.S. Food and Drug Administration approved the Cerene Cryotherapy Device in April 2019 for heavy menstrual bleeding, and the company later said it had completed more than 5,000 Cerene procedures by late 2025. Cerene markets the treatment as non-hormonal, incision-free, office-based, and done without anesthesia, with the procedure taking about 2.5 minutes and requiring minimal downtime. The device’s CLARITY study enrolled 242 women.

The education push also tracks with the broader clinical reality. The U.S. Office on Women’s Health says menopause does not happen all at once and that the average age of menopause in the United States is 52. The American College of Obstetricians and Gynecologists says bleeding changes are common in perimenopause, but bleeding between periods, after sex, heavier-than-usual bleeding or bleeding after menopause should still be discussed with an ob-gyn. That distinction is central for women trying to tell the difference between an expected transition and a symptom that needs workup.

The evidence base for education is stronger than the wellness industry often admits. A rapid review found menopause education programs can improve menopausal knowledge, symptoms and quality of life. A 2025 survey of 4,432 U.S. women looked at perimenopause symptoms and help-seeking, underscoring how common and variable the transition remains. The economic case is equally blunt: a Mayo Clinic Proceedings study estimated annual U.S. workday losses from menopause symptoms at $1.8 billion, and RAND has said symptoms can reduce productivity and support workplace policies and interventions. Cerene’s free series sits squarely in that gap between public-health need and brand opportunity.